CDK4 and breast cancer: Since 2018, CDK4/6 inhibitors (CDK4/6i) (e.g., palbociclib, ribociclib or abemaciclib) combined to endocrine therapy became the backbone of the treatment of HR + /HER2− breast cancer [6].